Document is current
Any future updates will be listed below
-
Authors
Plana, Deborah http://orcid.org/0000-0002-4218-1693
Fell, Geoffrey http://orcid.org/0000-0001-6436-6691
Alexander, Brian M.
Palmer, Adam C. http://orcid.org/0000-0001-5028-7028
Sorger, Peter K. http://orcid.org/0000-0002-3364-1838
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (T32-GM007753)
U.S. Department of Health & Human Services | National Institutes of Health (F30-CA260780, P50-GM107618, U54-CA225088)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
- License Information
-
More Information
Article History
Received: 14 June 2021
Accepted: 6 January 2022
First Online: 15 February 2022
Competing interests
: P.K. Sorger is a member of the SAB or Board of Directors of Applied Biomath, Glencoe Software, RareCyte Inc and has equity in these companies; he is a member of the SAB of NanoString Inc and a consultant for Merck and Montai Health. In the last five years the Sorger lab has received research funding from Novartis and Merck. Sorger declares that none of these relationships are directly or indirectly related to the content of this manuscript. B.M. Alexander is an employee of Foundation Medicine. No potential competing interests were disclosed by the other authors.
: All trials analyzed in this manuscript have been previously published (list found in Supplementary Data 1). Any information that could lead to the identification of an individual patient was not accessed, and no concerning ethical issue was raised in this research that would necessitate ethical approval or participant consent.
